Tahoe-100M, a giga-scale single-cell perturbation atlas comprising 100 million transcriptomes from 50 diverse cancer cell lines treated with 1,100 drug-dose conditions, advances the ability to model gene regulation, drug response, and network dynamics.
Abstract
We present Tahoe-100M, a giga-scale single-cell perturbation atlas comprising 100 million transcriptomes from 50 diverse cancer cell lines treated with 1,100 drug-dose conditions. This parallel profiling of thousands of perturbations at single-cell resolution with minimal batch effects is enabled by the Mosaic platform, which multiplexes genetically distinct cell models into balanced "cell villages." Beyond cataloging transcriptomic shifts, Tahoe-100M systematically quantifies cellular phenotypes, including proliferation, cytotoxicity, lineage-specific vulnerabilities, and cell-cycle changes. It captures population-level transcriptomic heterogeneity, characterizing whether drug responses drive cells toward divergent fates or convergent states. Pathway-based signatures define drug-induced expression programs, classify mechanisms of action, reveal off-target activities, and expose adaptive stress responses associated with resistance. By unifying cellular and molecular readouts, this broadly applicable perturbation atlas advances our ability to model gene regulation, drug response, and network dynamics. Its public release enables the training of AI frameworks to advance predictive models of cell behavior.
Single-cell sequencing offers profound insights into tumor complexity. However, reliably linking individual cellular profiles to overall sample-level phenotypes remains computationally challenging, particularly when cell-specific annotations are absent. This disconnect limits the technology’s utility in studying underl...
Zhen-Chao Tang, Fang Wang, Fan Yang et al.· Nature Communications· 2 citations
A single-cell regulatory network analysis of therapy-associated cell state remodeling to inform combination strategies in osteosarcoma and single-cell profiling reveals drug effects missed by bulk efficacy measures is extended.
J. Pavisic, Chelsey M. Burke, Dao-Qi You et al.· Cancer Research· 0 citations
Abstract Background Transcriptome-based drug repurposing can accelerate therapeutic discovery, but is limited by fragmented resources, inconsistent quality control, and reliance on single perturbation databases. Methods We developed CDRPipe ( C omputational D rug R epurposing Pipe line), a unified framework that interr...
Enock Niyonkuru, U. Khan, Xin-Yu Tang et al.· Research Square· 0 citations
Abstract Identification of new cell subtypes in single-cell RNA sequencing (scRNA-seq) data is critically crucial in accurately understanding the mechanisms of disease occurrence and development, which provides unprecedented insights into the development of therapeutic strategies, however, despite the abundance of exis...
Yue Yao, Xin Shao, Ren-Jie Chen et al.· Briefings in Bioinformatics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.